Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03419910 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
A Phase 1 study of Psoriasis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT03419910: Completed Phase 1 study of Psoriasis, sponsored by Bristol-Myers Squibb.
NCT03419910 is a Phase 1 study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 54 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03419910, a Phase 1 study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
Conditions Studied
Interventions
- DRUG Cyclosporine
- DRUG BMS-986165
Study Locations (1)
Utah
- PRA Health Sciences - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 1 |
What the finished NCT03419910 record still lists
NCT03419910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Cyclosporine is the first listed.
NCT03419910 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT03419910 about?
NCT03419910 is a clinical study titled "An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants". This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
What is the current status of trial NCT03419910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2018-03-05. Estimated completion is 2018-05-04.
What conditions does trial NCT03419910 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03419910?
The interventions under investigation include: Cyclosporine (DRUG), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03419910?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03419910 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03419910's enrollment target sits among peer trials
54 76th of 125 higher than 49 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI